USPTO serial 88177424
INNOVENT
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jan 5, 2021
- Examiner
- PATE,TARA J
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with INNOVENT?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $399*
Plus Government fees of $325
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Innovent Biologics (Suzhou) Co., Ltd.
Suzhou City, CN
Other trademarks owned by Innovent Biologics (Suzhou) Co., Ltd.
Innovent Biologics (Suzhou) Co., Ltd.
Suzhou City, CN
Other trademarks owned by Innovent Biologics (Suzhou) Co., Ltd.
Innovent Biologics (Suzhou) Co., Ltd.
Suzhou City, CN
Other trademarks owned by Innovent Biologics (Suzhou) Co., Ltd.
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Anessa Owen Kramer
Anessa Owen Kramer HONIGMAN LLP39400 WOODWARD AVENUE, SUITE 101BLOOMFIELD HILLS, MI 48304-5151UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medicines for human purposes, used for treating tumor, ophthalmology diseases, cardiovascular diseases, immune diseases, metabolic diseases, blood diseases, diabetes, endocrine system diseases, reproductive system diseases, respiratory system diseases, central and peripheral nervous system diseases, cancer, and antivirals; pharmaceutical preparations, used for treating tumor, ophthalmology diseases, cardiovascular diseases, immune diseases, metabolic diseases, blood diseases, diabetes, endocrine system diseases, reproductive system diseases, respiratory system diseases, central and peripheral nervous system diseases, cancer, and antivirals; drugs in the nature of pharmaceutical preparations for medical purposes, used for treating tumor, ophthalmology diseases, cardiovascular diseases, immune diseases, metabolic diseases, blood diseases, diabetes, endocrine system diseases, reproductive system diseases, respiratory system diseases, central and peripheral nervous system diseases, cancer, and antivirals; chemico-pharmaceutical preparations, used for treating tumor, ophthalmology diseases, cardiovascular diseases, immune diseases, metabolic diseases, blood diseases, diabetes, endocrine system diseases, reproductive system diseases, respiratory system diseases, central and peripheral nervous system diseases, cancer, and antivirals; chemical preparations for medical purposes, used for treating tumor, ophthalmology diseases, cardiovascular diseases, immune diseases, metabolic diseases, blood diseases, diabetes, endocrine system diseases, reproductive system diseases, respiratory system diseases, central and peripheral nervous system diseases, cancer, and antivirals; injectable preparations for medical purposes, used for treating tumor, ophthalmology diseases, cardiovascular diseases, immune diseases, metabolic diseases, blood diseases, diabetes, endocrine system diseases, reproductive system diseases, respiratory system diseases, central and peripheral nervous system diseases, cancer, and antivirals; biological preparations for medical purposes, used for treating tumor, ophthalmology diseases, cardiovascular diseases, immune diseases, metabolic diseases, blood diseases, diabetes, endocrine system diseases, reproductive system diseases, respiratory system diseases, central and peripheral nervous system diseases, cancer, and antivirals; vaccines; diagnostic preparations for medical purposes; dietetic foods adapted for medical use; biological tissue cultures for medical purposes; nutraceutical preparations for use as a dietary supplement for therapeutic or medical purposes | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Innovent Biologics (Suzhou) Co., Ltd.
- Other trademarks owned by Innovent Biologics (Suzhou) Co., Ltd.
- Other trademarks owned by Innovent Biologics (Suzhou) Co., Ltd.
- Other trademarks in Class 005
- Similar marks named INNOVENT
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jan 5, 2026 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Jan 5, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Oct 20, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 20, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 30, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 17, 2020 | ADBS | 1(B) BASIS DELETED; NEW BASIS REQUESTED | — |
| Sep 17, 2020 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| Sep 11, 2020 | ATRQ | ATTORNEY REVIEW/DECISION ON AMENDMENT REQUIRED | — |
| Sep 11, 2020 | PCBG | PETITION TO DIRECTOR - CHANGE BASIS - GRANTED | — |
| Sep 9, 2020 | APET | ASSIGNED TO PETITION STAFF | — |
| Jul 24, 2020 | TPAD | TEAS PETITION TO AMEND BASIS RECEIVED | — |
| Jun 16, 2020 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Apr 21, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 21, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 1, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 19, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 13, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 12, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 12, 2020 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Feb 26, 2020 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Feb 26, 2020 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Feb 26, 2020 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Aug 24, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 23, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 23, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 11, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 11, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 11, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 7, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 17, 2018 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Nov 16, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 5, 2018 | NWAP | NEW APPLICATION ENTERED | — |